Australia - English - Department of Health (Therapeutic Goods Administration)

hannah haniel pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

hannah haniel pty ltd - docosahexaenoic acid (dha)-rich oil derived from microalgae schizochytrium sp., quantity: 250 mg (equivalent: docosahexaenoic acid, qty 100 mg) - capsule, soft - excipient ingredients: soya oil; gelatin; glycerol; purified water - maintain/support healthy growth and development ; maintain/support brain health ; maintain/support nervous system health

Australia - English - Department of Health (Therapeutic Goods Administration)

hannah haniel pty ltd - cod-liver oil, quantity: 275 mg (equivalent: vitamin a, qty 100 re/microgram; equivalent: colecalciferol, qty 0.75 microgram); natural fish oil, quantity: 120 mg (equivalent: eicosapentaenoic acid, qty 21.6 mg; equivalent: docosahexaenoic acid, qty 14.4 mg) - capsule, soft - excipient ingredients: d-alpha-tocopherol; soya oil; gelatin; glycerol; purified water - maintain/support healthy eye function ; maintain/support healthy growth and development ; maintain/support learning and information processing ; maintain/support brain function ; maintain/support brain health

Australia - English - Department of Health (Therapeutic Goods Administration)

hannah haniel pty ltd - hydroxyapatite, quantity: 270 mg (equivalent: calcium, qty 78 mg); colecalciferol, quantity: 2.5 microgram - capsule, soft - excipient ingredients: white beeswax; lecithin; soya oil; gelatin; glycerol; purified water; titanium dioxide - aids/assists teeth development ; maintain/support (state mineral) absorption in bones ; maintain/support healthy immune system function ; maintain/support muscle function ; maintain/support absorption of dietary (state vitamin/mineral/nutrient)

Australia - English - Department of Health (Therapeutic Goods Administration)

hannah haniel pty ltd - docosahexaenoic acid (dha)-rich oil derived from microalgae schizochytrium sp., quantity: 525 mg (equivalent: docosahexaenoic acid, qty 210 mg) - capsule, soft - excipient ingredients: gelatin; glycerol; purified water - helps maintain/support healthy vision development ; maintain/support cognitive development ; maintain/support brain/central nervous system development ; helps maintains/support healthy foetal cns/brain development

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - trastuzumab, quantity: 600 mg - injection, solution - excipient ingredients: vorhyaluronidase alfa; histidine hydrochloride monohydrate; histidine; trehalose dihydrate; methionine; polysorbate 20; water for injections - early breast cancer: herceptin sc is indicated for the treatment of her2-positive localised breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer: herceptin sc is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant herceptin.,metastatic breast cancer: herceptin sc is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:,- as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,- in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,- in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.

South Africa - English - myHealthbox

bayer ag - fenhexamid (hydroxyanilide) 500 g/l

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 80 mg/ml; trastuzumab 40 mg/ml;   - solution for injection - active: pertuzumab 80 mg/ml trastuzumab 40 mg/ml   excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 60 mg/ml; trastuzumab 60 mg/ml;   - solution for injection - active: pertuzumab 60 mg/ml trastuzumab 60 mg/ml   excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Singapore - English - HSA (Health Sciences Authority)

mandarin opto-medic co pte ltd - ophthalmology - the hanna trephine system is intended for use in the cutting of corneas in corneal transplantation.